LYRA vs WORX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LYRA is in a state of severe financial distress, evidenced by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.25, indicating negative shareholder equity. The company has experienced a catastrophic revenue collapse of -96.70% YoY and an extreme operating margin of -98,728.57%. With a 52-week high of $37.50 now trading at $0.65, the stock has lost nearly all its value. The combination of negative equity, vanishing revenue, and bearish insider activity suggests a high risk of insolvency.
SCWorx Corp exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is experiencing a catastrophic price collapse, with a 5-year decline of 99.7% and a recent 1-month drop of 47.5%. Despite a low debt-to-equity ratio and modest revenue growth of 13.8%, the profit margin of -154.44% and an ROE of -76.35% demonstrate an unsustainable business model that is rapidly eroding shareholder equity.
Compare Another Pair
Related Comparisons
LYRA vs WORX: Head-to-Head Comparison
This page compares Lyra Therapeutics, Inc. (LYRA) and SCWorx Corp. (WORX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.